Shin-Ichi Hayashi
Overview
Explore the profile of Shin-Ichi Hayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
2114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sakamoto T, Tanimoto K, Eguchi H, Sasaki S, Tsuboi K, Hayashi S, et al.
Breast Cancer
. 2023 May;
30(5):727-738.
PMID: 37166625
Background: Triple-negative breast cancer (TNBC) has an aggressive phenotype and poor outcome, however no specific targeted therapy has been established for TNBC lacking germline BRCA1/2 pathogenic variants. To develop a...
2.
Gohno T, Hanamura T, Kurosumi M, Takei H, Yamaguchi Y, Hayashi S
Anticancer Res
. 2022 Jan;
42(2):759-766.
PMID: 35093874
Background/aim: Carboxyl terminus of Hsc70-interacting protein (CHIP) is a ubiquitin ligase that induces ubiquitination and degradation of its target proteins including oncoproteins. We reported that its down-regulation is associated with...
3.
Suzuki Y, Wenwen W, Ohta T, Hayashi S
Breast Cancer
. 2021 Aug;
29(1):185.
PMID: 34420190
No abstract available.
4.
Suzuki Y, Wenwen W, Ohta T, Hayashi S
Breast Cancer
. 2021 Aug;
29(1):77-91.
PMID: 34346034
Background: There are various treatments for estrogen-positive breast cancer, mainly hormone therapy and molecular-targeted drugs. Acquiring resistance to these drugs is a major clinical problem. Additionally, little is known about...
5.
Murata A, Hayashi S
Front Immunol
. 2020 Jun;
11:775.
PMID: 32508808
In allergic contact dermatitis (ACD) and contact hypersensitivity (CHS), the healed skin shows greater swelling than the naïve skin in the same individual upon re-exposure to the same hapten. This...
6.
Fukui F, Hayashi S, Yamaguchi Y
J Steroid Biochem Mol Biol
. 2020 May;
201:105698.
PMID: 32404282
Estrogen receptor (ER)α and the human epidermal growth factor receptor (HER) family are inversely expressed in ERα-positive cancer in association with resistance to hormonal therapy, but the mechanism underlying their...
7.
Iida M, Toyosawa D, Nakamura M, Tsuboi K, Tokuda E, Niwa T, et al.
Breast Cancer
. 2020 Apr;
27(5):963-972.
PMID: 32297248
Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors represent a significant advancement in the treatment of estrogen receptor (ER)-positive human epidermal growth factor receptor 2-negative advanced breast cancer. However, mechanisms of alterations...
8.
Niwa T, Takanobu J, Suzuki K, Sato Y, Yamaguchi Y, Hayashi S
J Steroid Biochem Mol Biol
. 2020 Apr;
201:105671.
PMID: 32289430
The estrogen receptor (ER) plays a role in the progression of hormone-dependent breast cancer and is a hormone therapy target. Estrogen acts as a transcription factor (genomic action) and also...
9.
Iida M, Nakamura M, Tokuda E, Toyosawa D, Niwa T, Ohuchi N, et al.
Oncotarget
. 2019 Aug;
10(47):4907-4918.
PMID: 31448056
Although cyclin-dependent kinase (CDK) 4/6 inhibitors have exhibited remarkable results for patients with estrogen receptor (ER)-positive breast cancer in clinical trials, the mechanism of CDK4/6 inhibitor resistance remains unclear. Thus,...
10.
Tsuboi K, Uematsu C, Yamaguchi Y, Niwa T, Hayashi S
Breast Cancer
. 2019 May;
26(6):748-757.
PMID: 31119683
Background: Hormonal therapy is an effective treatment for luminal-like breast cancer. Aromatase inhibitor (AI) is widely used for estrogen receptor-positive, postmenopausal breast cancers. However, resistance is occurred and becomes a...